$157.06
Insights on Repligen Corp
Revenue is up for the last 2 quarters, 141.19M → 155.74M (in $), with an average increase of 9.3% per quarter
Netprofit is down for the last 5 quarters, 48.72M → -25.48M (in $), with an average decrease of 80.2% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 44.4%
In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 62.6%
2.69%
Downside
Day's Volatility :4.08%
Upside
1.43%
29.68%
Downside
52 Weeks Volatility :47.69%
Upside
25.61%
Period | Repligen Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -7.59% | -0.7% | 0.0% |
6 Months | 12.96% | 6.6% | 0.0% |
1 Year | -5.36% | 3.7% | -1.5% |
3 Years | -24.08% | 14.0% | -21.8% |
Market Capitalization | 9.2B |
Book Value | $35.35 |
Earnings Per Share (EPS) | 0.74 |
PE Ratio | 221.85 |
PEG Ratio | 2.59 |
Wall Street Target Price | 204.62 |
Profit Margin | 6.51% |
Operating Margin TTM | 5.14% |
Return On Assets TTM | 1.31% |
Return On Equity TTM | 2.14% |
Revenue TTM | 638.8M |
Revenue Per Share TTM | 11.46 |
Quarterly Revenue Growth YOY | -16.6% |
Gross Profit TTM | 455.7M |
EBITDA | 124.3M |
Diluted Eps TTM | 0.74 |
Quarterly Earnings Growth YOY | -0.55 |
EPS Estimate Current Year | 1.46 |
EPS Estimate Next Year | 2.07 |
EPS Estimate Current Quarter | 0.33 |
EPS Estimate Next Quarter | 0.35 |
What analysts predicted
Upside of 30.28%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 194.0M | ↑ 37.38% |
Net Income | 16.6M | ↓ 41.39% |
Net Profit Margin | 8.56% | ↓ 11.51% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 270.2M | ↑ 39.28% |
Net Income | 21.4M | ↑ 28.85% |
Net Profit Margin | 7.92% | ↓ 0.64% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 366.3M | ↑ 35.53% |
Net Income | 59.9M | ↑ 179.88% |
Net Profit Margin | 16.36% | ↑ 8.44% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 670.5M | ↑ 83.08% |
Net Income | 128.3M | ↑ 114.08% |
Net Profit Margin | 19.13% | ↑ 2.77% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 801.5M | ↑ 19.54% |
Net Income | 186.0M | ↑ 44.95% |
Net Profit Margin | 23.2% | ↑ 4.07% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 638.8M | ↓ 20.31% |
Net Income | 41.6M | ↓ 77.64% |
Net Profit Margin | 6.51% | ↓ 16.69% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 200.7M | ↓ 3.32% |
Net Income | 40.4M | ↓ 18.96% |
Net Profit Margin | 20.13% | ↓ 3.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 186.8M | ↓ 6.96% |
Net Income | 48.7M | ↑ 20.6% |
Net Profit Margin | 26.09% | ↑ 5.96% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 182.7M | ↓ 2.2% |
Net Income | 28.8M | ↓ 40.84% |
Net Profit Margin | 15.78% | ↓ 10.31% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 159.2M | ↓ 12.86% |
Net Income | 20.1M | ↓ 30.4% |
Net Profit Margin | 12.61% | ↓ 3.17% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 141.2M | ↓ 11.29% |
Net Income | 18.2M | ↓ 9.43% |
Net Profit Margin | 12.87% | ↑ 0.26% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 155.7M | ↑ 10.31% |
Net Income | -25.5M | ↓ 240.26% |
Net Profit Margin | -16.37% | ↓ 29.24% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 139.5M | ↑ 15.81% |
Total Liabilities | 155.0M | ↑ 2.04% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 904.03% |
Total Liabilities | 340.3M | ↑ 119.55% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 35.91% |
Total Liabilities | 373.7M | ↑ 9.81% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.4B | ↑ 23.94% |
Total Liabilities | 608.3M | ↑ 62.76% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.5B | ↑ 7.05% |
Total Liabilities | 614.0M | ↑ 0.93% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.8B | ↑ 11.87% |
Total Liabilities | 853.2M | ↑ 38.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 0.72% |
Total Liabilities | 627.4M | ↓ 1.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 2.52% |
Total Liabilities | 614.0M | ↓ 2.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 0.54% |
Total Liabilities | 597.7M | ↓ 2.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↑ 0.42% |
Total Liabilities | 578.1M | ↓ 3.29% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.5B | ↓ 1.37% |
Total Liabilities | 525.6M | ↓ 9.08% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.8B | ↑ 12.34% |
Total Liabilities | 853.2M | ↑ 62.34% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 32.8M | ↑ 87.78% |
Investing Cash Flow | -14.0M | ↓ 85.71% |
Financing Cash Flow | 3.4M | ↓ 97.38% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 67.2M | ↑ 105.11% |
Investing Cash Flow | -205.3M | ↑ 1362.62% |
Financing Cash Flow | 484.9M | ↑ 14131.49% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.6M | ↓ 6.83% |
Investing Cash Flow | -201.4M | ↓ 1.91% |
Financing Cash Flow | 305.9M | ↓ 36.91% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 119.0M | ↑ 90.05% |
Investing Cash Flow | -221.2M | ↑ 9.82% |
Financing Cash Flow | 961.0K | ↓ 99.69% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 172.1M | ↑ 44.59% |
Investing Cash Flow | -233.2M | ↑ 5.46% |
Financing Cash Flow | -13.3M | ↓ 1487.83% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 41.4M | ↓ 9.52% |
Investing Cash Flow | -57.5M | ↑ 119.28% |
Financing Cash Flow | 1.3M | ↓ 154.56% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 61.9M | ↑ 49.59% |
Investing Cash Flow | -121.3M | ↑ 110.99% |
Financing Cash Flow | -274.0K | ↓ 121.9% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 11.2M | ↓ 81.98% |
Investing Cash Flow | -9.4M | ↓ 92.22% |
Financing Cash Flow | -9.6M | ↑ 3390.15% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 34.5M | ↑ 209.02% |
Investing Cash Flow | 64.8M | ↓ 787.3% |
Financing Cash Flow | -8.8M | ↓ 7.72% |
Sell
Neutral
Buy
Repligen Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Repligen Corp | -17.13% | 12.96% | -5.36% | -24.08% | 193.97% |
Intuitive Surgical, Inc. | -4.7% | 35.81% | 38.95% | 38.38% | 112.57% |
Resmed Inc. | -8.97% | 22.05% | -22.01% | -15.48% | 75.2% |
Becton, Dickinson And Company | -2.32% | -10.48% | -8.43% | -10.33% | 1.9% |
West Pharmaceutical Services Inc | -4.64% | 0.62% | 4.23% | 19.12% | 238.38% |
Alcon Ag | -6.1% | 7.94% | 11.1% | 7.08% | 42.78% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Repligen Corp | 221.85 | 221.85 | 2.59 | 1.46 | 0.02 | 0.01 | NA | 35.35 |
Intuitive Surgical, Inc. | 75.26 | 75.26 | 7.13 | 6.25 | 0.15 | 0.08 | NA | 37.77 |
Resmed Inc. | 30.61 | 30.61 | 1.75 | 7.41 | 0.22 | 0.11 | 0.01 | 30.47 |
Becton, Dickinson And Company | 52.86 | 52.86 | 1.34 | 12.95 | 0.05 | 0.03 | 0.02 | 87.68 |
West Pharmaceutical Services Inc | 48.1 | 48.1 | 6.72 | 7.62 | 0.21 | 0.12 | 0.0 | 39.2 |
Alcon Ag | 40.62 | 40.62 | 4.59 | 3.06 | 0.05 | 0.02 | 0.0 | 41.81 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Repligen Corp | Buy | $9.2B | 193.97% | 221.85 | 6.51% |
Intuitive Surgical, Inc. | Buy | $134.2B | 112.57% | 75.26 | 25.24% |
Resmed Inc. | Buy | $27.2B | 75.2% | 30.61 | 19.77% |
Becton, Dickinson And Company | Buy | $67.8B | 1.9% | 52.86 | 6.44% |
West Pharmaceutical Services Inc | Buy | $27.8B | 238.38% | 48.1 | 20.12% |
Alcon Ag | Buy | $39.5B | 42.78% | 40.62 | 10.3% |
BlackRock Inc
Vanguard Group Inc
T. Rowe Price Associates, Inc.
FMR Inc
State Street Corporation
Brown Capital Management, LLC
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Organization | Repligen Corp |
Employees | 1783 |
CEO | Mr. Anthony J. Hunt |
Industry | Health Technology |
Endeavor Group Holdings, Inc.
$157.06
-2.44%
Associated Banc-corp
$157.06
-2.44%
Assetmark Financial Holdings Inc
$157.06
-2.44%
Essential Utilities Inc.
$157.06
-2.44%
Vanguard Ultra Short Bond Et
$157.06
-2.44%
Surgery Partners Inc
$157.06
-2.44%
Sl Green Realty Corp.
$157.06
-2.44%
Janus Henderson Mortgage-backed Securities Etf
$157.06
-2.44%
Goldman Sachs Activebeta Int
$157.06
-2.44%